Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.” ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...

Across the recent three months, 11 analysts have shared their insights on Arcellx (NASDAQ:ACLX), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.